Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG). (February 2022)

• Record Type: Journal Article
• Authors: Martin, D.; Schreckenbach, T.; Ziegler, P.; Filmann, N.; Kalinauskaite, G.; Tinhofer, I.; Budach, V.; Gani, C.; Zips, D.; Schimek-Jasch, T.; Schäfer, H.; Grosu, A.L.; Thomas, E.; Krause, M.; Dapper, H.; Combs, S.; Hoffmann, C.; Stuschke, M.; Walter, F.; Belka, C.; Kurth, I.; Hadiwikarta, W.W; Baumann, M.; Rödel, C.; Fokas, E.
• Is Part Of: Radiotherapy and oncology. Volume 167(2022)
• Page Start: 233
• Page End: 238
• Publication Date: 2022-02
• Subjects: Anal cancer -- Chemoradiotherapy -- Prognostic factors -- Cox regression; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2021.12.050
• Languages: English
• ISSNs: 0167-8140

Abstract

Highlights: Multicentric cohort of n = 605 patients treated with definitive chemoradiotherapy for anal cancer. Overall, T-category, N-category, age and KPS were associated with worse DFS. In early stage disease, T-category, HIV status, age, performance status and elevated platelets were associated with worse DFS. Abstract: Background and purpose: Prognosis after chemoradiotherapy (CRT) for anal squamous cell carcinoma (ASCC) shows marked differences among patients according to TNM subgroups, however individualized risk assessment tools to better stratify patients for treatment (de-) escalation or intensified follow-up are lacking in ASCC. Materials and methods: Patients' data from eight sites of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG), comprising a total of 605 patients with ASCC, treated with standard definitive CRT with 5-FU/Mitomycin C or Capecitabine/Mitomycin C between 2004–2018, were used to evaluate prognostic factors based on Cox regression models for disease-free survival (DFS). Evaluated variables included age, gender, Karnofsky performance score (KPS), HIV-status, T-category, lymph node status and laboratory parameters. Multivariate cox models were separately constructed for the whole cohort and the subset of patients with early-stage (cT1-2 N0M0) tumors. Results: After a median follow-up of 46 months, 3-year DFS for patients with early-stage ASCC was 84.9%, and 67.1% for patients with locally-advanced disease (HR 2.4, p < 0.001). T-category (HR vs. T1: T2 2.02; T3 2.11; T4 3.03), N-category (HR versus N0: 1.8 for N1-3), age (HR 1.02 per year), and KPS (HR 0.8 per step) were significant predictors for DFS in multivariate analysis in the entire cohort. The model performed with a C-index of 0.68. In cT1-2N0 patients, T-category (HR 2.14), HIV status (HR 2.57), age (1.026 per year), KPS (HR 0.7 per step) and elevated platelets (HR 1.3 per 100/nl) were associated with worse DFS (C-index of 0.7). Conclusion: Classical clinicopathologic parameters like T-category, N-category, age and KPS remain to be significant prognostic factors for DFS in patients treated with contemporary CRT for ASCC. HIV and platelets were significantly associated with worse DFS in patients with early stage ASCC.